Overview

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

Status:
Completed

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal (IVT) administration of DE-122 in subjects with refractory exudative age-related macular degeneration (AMD).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Santen Inc.

Treatments:

Pharmaceutical Solutions